SCHEMBL339004

SCHEMBL339004

CC(=O)c1cc(N2CCCC2)ccc1NC(=O)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.66
ALDH1A1 P00352 3/20 0.66
LMNA P02545 3/20 0.66
KDM4E B2RXH2 2/20 0.66
NPSR1 Q6W5P4 1/20 0.66
KMT2A Q03164 4/20 0.66
USP2 O75604 1/20 0.66
MAPK1 P28482 1/20 0.66
ESR2 Q92731 1/20 0.66
TAAR1 Q96RJ0 1/20 0.66
HPGD P15428 1/20 0.64
HTT P42858 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
TSHR P16473 2/20 0.60
GAA P10253 1/20 0.60
MEN1 O00255 3/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
NR1H4 Q96RI1 1/20 0.54
MAOB P27338 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL340905 0.92 ALDH1A1 (0.66) MAPTALDH1A1LMNAKDM4ENPSR1
SCHEMBL341381 0.90 MAPT (0.63) MAPTALDH1A1LMNAKDM4ENPSR1
SCHEMBL22778811 0.85 MAPT (0.81) MAPTALDH1A1LMNAKDM4ENPSR1
SCHEMBL341059 0.84 MEN1 (0.61) MAPTALDH1A1KDM4EKMT2AUSP2
SCHEMBL339293 0.83 LRRK2 (0.63) MAPTKMT2AGAAMEN1NPC1
SCHEMBL341357 0.82 KMT2A (0.69) MAPTALDH1A1LMNAKDM4ENPSR1
SCHEMBL340956 0.80 KMT2A (0.62) MAPTALDH1A1LMNAKDM4ENPSR1
SCHEMBL17740323 0.79 MAPT (1.00) MAPTALDH1A1LMNAKDM4ENPSR1
SCHEMBL341625 0.77 MEN1 (0.60) MAPTALDH1A1KDM4EKMT2AUSP2
SCHEMBL340622 0.76 MAPT (0.68) MAPTALDH1A1LMNAKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3112348-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES Tairx, Inc. (TW) 2017-01-04 EP disclosed
EP-2593435-B1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES TAIRX INC (TW) 2016-09-07 EP disclosed
CN-103347859-B Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives EFFICIENT PHARMA MANAGEMENT CORP. (CN) 2015-12-02 CN disclosed
CN-103347859-A Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives EFFICIENT PHARMA MAN CORP 2013-10-09 CN disclosed
US-8524740-B2 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives TAIRX, INC. (TW) 2013-09-03 US disclosed
EP-2593435-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES Tairx, Inc. (TW) 2013-05-22 EP disclosed
WO-2012009519-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES EFFICIENT PHARMA MANAGEMENT CORP. (TW) 2012-01-19 WO disclosed
US-20120015908-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES Efficient Pharma Management Corporate (TW) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015908-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES SLC22A8, ABCC8, CYP2C8 MAPT 4760/4885ALDH1A1 1258/4885LMNA 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.